[Biological properties and clinical application of filgrastim (G-CSF)]
- PMID: 7504384
[Biological properties and clinical application of filgrastim (G-CSF)]
Abstract
Granulocyte--colony stimulating factor (G-CSF, filgrastim) is a glycoprotein hormone of the hematopoietin family that primarily influences the proliferation and differentiation of neutrophilic granulocytic precursors. As with all glyco-protein hormones, G-CSF interacts with target cells by binding to specific cell-surface receptors. It stimulates proliferation, differentiation and activation of cells of the neutrophil--granulocyte lineage and has been investigated as therapy for patients with various neutropenic conditions. A major use for recombinant G-CSF therapy will be in ameliorating the neutropenia which follows cytoreductive chemotherapy. The increase in neutrophils produced by this factor render it a useful treatment for conditions such as congenital, acquired and cyclic neutropenias. It may be an effective therapy in myelodysplasia and aplastic anaemia. G-CSF is also useful in accelerating the recovery of transplanted bone marrow in patients with leukaemia, lymphoma and solid tumors. G-CSF is well tolerated. The most frequently reported adverse effect is mild to moderate bone pain.
Similar articles
-
[GM-CSF and G-CSF: cytokines in clinical application].Schweiz Med Wochenschr. 1991 Mar 23;121(12):397-412. Schweiz Med Wochenschr. 1991. PMID: 1709294 Review. German.
-
Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions.Drugs. 1991 Aug;42(2):300-30. doi: 10.2165/00003495-199142020-00009. Drugs. 1991. PMID: 1717226 Review.
-
Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.Exp Hematol. 1995 Dec;23(14):1520-6. Exp Hematol. 1995. PMID: 8542941
-
[Biologic aspects and clinical use of granulocyte growth factor].Recenti Prog Med. 1995 Dec;86(12):510-7. Recenti Prog Med. 1995. PMID: 8588087 Review. Italian.
-
Clinical effects of biologic response modifiers.Am J Hosp Pharm. 1993 Jul;50(7 Suppl 3):S10-8. Am J Hosp Pharm. 1993. PMID: 7689788 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials